Analyst Price Targets — TRVI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 8, 2026 11:34 am | Annabel Samimy | Stifel Nicolaus | $30.00 | $14.05 | TheFly | Trevi Therapeutics price target raised to $30 from $18 at Stifel |
| May 6, 2026 11:15 am | — | Morgan Stanley | $20.00 | $14.66 | TheFly | Trevi Therapeutics price target raised to $20 from $18 at Morgan Stanley |
| December 19, 2025 12:50 pm | — | Stifel Nicolaus | $18.00 | $12.19 | TheFly | Trevi Therapeutics price target raised to $18 from $15 at Stifel |
| November 19, 2025 10:23 am | Roanna Ruiz | Leerink Partners | $16.00 | $11.31 | StreetInsider | Trevi Therapeutics (TRVI) PT Raised to $16 at Leerink Partners |
| November 14, 2025 1:19 pm | Judah Frommer | Morgan Stanley | $19.00 | $11.68 | TheFly | Trevi Therapeutics price target raised to $19 from $18 at Morgan Stanley |
| November 14, 2025 11:51 am | Leland Gershall | Oppenheimer | $24.00 | $11.80 | StreetInsider | Trevi Therapeutics (TRVI) PT Raised to $24 at Oppenheimer |
| October 22, 2024 6:59 am | Oren Livnat | H.C. Wainwright | $6.00 | $3.35 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Trevi Therapeutics (TRVI) |
| October 4, 2024 12:48 pm | Mayank Mamtani | B.Riley Financial | $6.00 | $3.02 | StreetInsider | B.Riley Reiterates Buy Rating on Trevi Therapeutics (TRVI) |
| July 9, 2022 3:59 pm | Leland Gershall | Oppenheimer | $12.00 | $3.95 | Pulse 2.0 | Trevi Therapeutics (TRVI) Stock: $12 Target And Outperform Rating |
Latest News for TRVI
NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management…
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Trevi Therapeutics NASDAQ: TRVI outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent financing.
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TRVI.
U.S. House Trading
No House trades found for TRVI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.